Improving Treatment of Diseases with Rapid Therapeutic Discovery
Advances in synthetic and molecular biology have accelerated the discovery and optimization of therapeutic proteins, known as Biologics.
Streamlined Antibody Development
Biologics are an important class of drugs for the treatment of a wide spectrum of disorders, including autoimmune, metabolic, neurologic, infectious diseases, cancer, and more. Twist Biopharma, a division of Twist Bioscience, leverages our team of experts and precise library technology to build focused phage display libraries for biologic drug discovery.
Innovative Technology
High throughput DNA synthesis underpins the rapid expansion of discovery and optimization efforts in the biologics discovery space. Twist Bioscience’s unique DNA writing technology enables the synthesis of millions of DNA oligonucleotides simultaneously with unparalleled diversity and precision coupled with game-changing throughput and quality.
Libraries for Antibody Development
In-house, these same oligo pools underpin our Synthetic Protein Library technology. Researchers use our Site-Saturation Variant Libraries and Combinatorial Variant Libraries for the discovery and optimization of new biologic candidates.
Oligo Pools for Target Identification
Industrial researchers utilize our oligo pools to power high throughput functional genomics screens for target identification and validation.
Partnerships for Full Biologics Programs
Twist Biopharma uses our library technology to build focused phage display libraries. Through multiple rounds of binding selection, we enrich for high-affinity clones which provides the basis for our antibody discovery optimization services.
High Throughput Functional Screens to Identifty Druggable Targets
While Twist’s oligo pools form the foundation for synthetic library synthesis, scientists also use them to undertake high throughput screens that drive the identification of new druggable targets, including high throughput peptide discovery screens, and high throughput functional genomic screens like CRISPR and FISH. Hear from Dr. Benedict Cross from PhoreMost about how they discover new druggable targets using Twist’s long oligos in their SITESEEKER platform.
Enhancing the Therapeutic Properties of a Cancer-Targeting Affibody
See how researchers at the at the KTH Royal Institute of Technology and Uppsala University are using Twist’s Combinatorial Variant Libraries to engineer previously identified affibody molecules targeting VEGFR2 for basic biological research into the vascularization process and potentially target the treatment of several diseases including cancer and macular degeneration.
Comprehensive Drug Discovery Guide
Still in need of more information on what exactly that journey looks like going from a target to a molecule? Twist Biopharma is here to support you through the journey.
This process is long, with most companies taking approximately 12 years to move from the first patent filing to FDA approval. The multi-year journey may feel overwhelming, but it can be broken up into short-term goals and milestones as you will see in this comprehensive Antibody Discovery and Development Guide.
